IMWG Conference Series: Making Sense of Treatment June 15, 2023 1
Thank you to our sponsors!
2
Topics to be covered
ASCO 2023 Annual Meeting – June 2-6, Chicago
IMWG Summit – June 7-8, Frankfurt
EHA 2023 Hybrid Congress – June 9-12, Frankfurt
•
•
•
3
Notable Event: 2023 Kyle & Durie Achievement Awards
4
Congratulations!
Maria-Victoria Mateos, MD, PhD
Recipientof the 2023 RobertA. Kyle Lifetime AchievementAward
Thomas Martin, MD
Recipientof the 2023 Brian G.M.Durie Outstanding AchievementAward
Top Abstract
at ASCO and EHA (Plenary)
• Cilta-cel (CAR T) v SOC in Early Relapse presented duringthe Special CAR T Sessionat ASCO 2023
• Impressiveresults:Progressionrisk reducedby74%
• Companion NEJM Publication: Points to useof CAR T in Earlier Disease
5
6
7
8
Discussion
9
ASCO: Main Oral Session
Saturday, June 3
• Abstract #8000: KRd vs Elo KRd in NDMM
• Abstract #8001: KPd maintenance in High-risk MM
• Abstract #8002: Teclistamab + Talquetamab (RedirecTT-1)*****
• Abstract #8003: Talquetamab + Dara (TRiMM-2)
• Abstract #8004: Phase 1 CAR T: PHE 885
• Abstract #8005: Rapid CAR T dual target – Shanghai experience
• Abstract #8006: Bispecific Regeneron #5458 (LINKER-MM1)
• Abstract #8007: DREAMM-3 Bela versus Pom dex F/U
• Abstract #8008: Bispecific Elranatamab: MagnetisMM
*****Will be discussed infull
10
Additional ASCO Presentations
SPECIAL POPULATIONS: Age/Disparities/Renal Compromise
Meet the Prof on Bispecifics: Moreau/Garfall
Wide range of topics
ORALS/POSTERS
•
•
•
11
EHA 2023 Presentations
Over 200 interesting/important Myeloma Abstracts!
Some TOP ABSTRACTS are also from ASCO 2023
Many unique presentations that are impossible to summarize:
❑ Immune therapies (CAR T/Bispecifics)
❑ Combinations
❑ Real-world findings
❑ Patients’Preferences
❑ Infections
❑ QoL
❑ DREAMM studies
❑ Master Trial
❑ Selinexor combos
❑ Zometa 4 years
❑ Young outcomes
❑ Telomeres
❑ EMD
❑ Arginine Deprivation
❑ MRDSurrogacy
•
•
•
12
Discussion
13
14
Discussion
15
16
Discussion
17
18
19
20
21
Discussion
22
23
Turning to IMWG Summit Key Discussions
24
Smoldering Multiple Myeloma Committee Report
María-Victoria Mateos, MD, PhD
University of Salamanca, Spain
Shaji Kumar, MD Mayo Clinic
25
Diagnosis
• Stress importance of confirmation of numbers – also confirms stability/opportunity to observe evolution
• Patients with risk of progression >=80% @ 2 years were reclassified as active MM in 2014
• New risk stratificationhas the highest risk group with progression risk of 72% at the highest, a small group of patients –reclassification?
• Distinction between MGUS and SMM – important form a clinical standpoint, biology is a continuum
26
27
Endpoints for trials
• What would be the right endpoint for trials?
– Overall survival is the gold standard but will take many years to find the benefit
• Progression free survival?
• Sustained MRD negativity? If so, how long?
• HRQOL endpoints?
28
Discussion
29
Challenges for trial design: “Relapsed SMM”
• If we go with biochemical progression, are they still smoldering when they progress?
• Can they go on another smoldering trial?
• If we wait for CRAB features, then are they considered newly diagnosed MM for a clinical trial?
• Likely the easiest option would be to consider them as relapsed MM with one prior line – if they were treated with a MM type regimen
30
Combined Mass Spectrometry & MRD Committee Report
Mass Spectrometry
Brian G.M. Durie, MD
International Myeloma Foundation
David Murray, MD, PhD
Mayo Clinic
MRD
Nikhil Munshi, MD
Dana-Farber Cancer Institute
Bruno Pavia, PhD
University of Navarra
31
Mayo Update
• Performed over 200,000 tests by Mass Spec since 2018
– Retrospectivereviewof first20,000 tests published(Mayo ClinicProceedings)
• Urine Mass Spec is clinically available as of two weeks ago
– Equal sensitivityto urineIFE withoutconcentrating theurine
– Improvedspecificityasmass of lightchains consistentwithserum
• Eliminationof SPEP Dec 2023
Literature Update
• Several New Papers using a targetedCDR M-proteinpeptides for MRD
–
–
“EasyM”test from Universityof WashingtoninSt. Louis
Sebia/Erasmus UniversityMRD
• Detectionin Non-Secretory MM (Giles et al Blood)
• Low-Cost Method using MALDi-TOF (Mehra et al)
Commercialization Update
• Europe planned for August 2023
• USAplanned for Q1 2024
32
Why Mass Spec could be routine in most labs
• Lab workflow/through put is significantly increased
–
Mayo has tripled the number of results per lab tech for IFE
– This will increase again on replacement of SPEP
• Current cost for U.S. Medicare patients is only 25% of a serum
rFLC determination
• Detection of other new entities and diseases
–
IgG4 RD patterns are recognizable by this method
– Replacement for oligoclonal banding for MS
–
M-protein light chain glycosylation
•
Amyloidosis
• Cold AgglutininDisease
33
34
35
36
37
Guidelines to use MRD in clinical practice
Methods
38
•
• Frequency • Sampling •
• Patients
Time points
•
•
• Etc.
Reporting
Interpretation
Discussion
39
IMWG Summit Takeaways
❖ Many new projects (Registry/Biobank)
❖ Publications pending/planned
❖ New Areas of Focus:
o Infections
o QoL/Patients’ Perspective & Preferences
o Real-world role of MRD and Mass Spectrometry
o Many others for F/U before ASH Breakfast Meeting
40
”The Plasma Cells” IMWG Band
Zamagni,
Zweegman,MD,PhD;Philippe Moreau,MD;PaulaRodríguez-Otero,MD,PhD
41
Fromlefttoright:FrancescaGayMD,PhD;AlessandraLaRocca,MD,PhD;Elena
MD,PhD;EnriqueOcio,MD,PhD;S.VincentRajkumar,MD;Sonja
Discussion
42
We Want to Hear FromYou!
Feedback Survey
At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey.
This will also be emailed to you shortly after the workshop.
Please take a moment to complete this survey.
Thank you to our sponsors!
44
45
